Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy
2024

Combination Therapy for Membranous Nephropathy

Sample size: 26 publication 10 minutes Evidence: moderate

Author Information

Author(s): Vink Coralien H., Wetzels Jack F.M., Logt Anne-Els van de

Primary Institution: Radboud University Medical Centre

Hypothesis

Can a low-dose combination therapy with rituximab, cyclophosphamide, and prednisone improve outcomes in patients with membranous nephropathy?

Conclusion

Low-dose triple therapy induced a rapid immunological and clinical remission in most patients with membranous nephropathy.

Supporting Evidence

  • 88% of patients achieved immunological remission within 8 weeks.
  • 21 out of 26 patients developed proteinuria remission after initial therapy.
  • Patients needing additional therapy were identified by PLA2Rab half-life.

Takeaway

This study shows that a special mix of medicines can help most kids with a kidney problem feel better quickly.

Methodology

Single-arm prospective cohort study with high-risk, anti-PLA2R antibodies-positive patients.

Potential Biases

Potential bias due to the single-arm design and lack of randomization.

Limitations

The study had a small number of patients and lacked a validation cohort.

Participant Demographics

15 males, mean age 57 ± 14 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.ekir.2024.08.033

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication